Investors’ Concerns Hit Lantheus Holdings (LNTH) Stock in Q4
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. Small-cap stocks posted solid returns in the fourth quarter for the first time in 2022. The Russell 2000 Growth Index was up 4.11% trailing the Russell 2000 Value Index, which returned 8.39% in the quarter. For the year 2022, small-cap stocks posted disappointing results. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.
Carillon Eagle Small Cap Growth Fund highlighted stocks like Lantheus Holdings, Inc. (NASDAQ:LNTH) in the Q4 2022 investor letter. Based in North Billerica, Massachusetts, Lantheus Holdings, Inc. (NASDAQ:LNTH) is a manufacturer of diagnostic and therapeutic products. On February 1, 2023, Lantheus Holdings, Inc. (NASDAQ:LNTH) stock closed at $58.64 per share. One-month return of Lantheus Holdings, Inc. (NASDAQ:LNTH) was 19.82%, and its shares gained 124.50% of their value over the last 52 weeks. Lantheus Holdings, Inc. (NASDAQ:LNTH) has a market capitalization of $4.036 billion.
Carillon Eagle Small Cap Growth Fund made the following comment about Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q4 2022 investor letter:
"Lantheus Holdings, Inc. (NASDAQ:LNTH) provides imaging diagnostics, targeted therapeutics, and artificial intelligence solutions used to fight serious medical conditions. Despite another strong quarterly update, the stock came under pressure due in part to investor concerns regarding a possible deceleration of revenue growth in the company’s leading product, Pylarify, as the company seems to have penetrated most of the early adopters of this imaging agent for prostate cancer. Later in the quarter, the company announced a strategic collaboration and exclusive licensing agreement for two late-stage therapeutic products used for the treatment of metastatic prostate cancer and neuroendocrine tumors. We believe approval of these products should help offset any significant declines in revenue growth of Pylarify."
Ikonoklast Fotografie/Shutterstock.com
Lantheus Holdings, Inc. (NASDAQ:LNTH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Lantheus Holdings, Inc. (NASDAQ:LNTH) at the end of the third quarter which was 39 in the previous quarter.
We discussed Lantheus Holdings, Inc. (NASDAQ:LNTH) in another article and shared the list of AI healthcare stocks. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
Disclosure: None. This article is originally published at Insider Monkey.
